ASH 2023 | Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents
Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, discusses data from a retrospective real-world analysis of treatment patterns among patients with myelodysplastic syndromes (MDS) receiving oral decitabine and cedazuridine (DEC-C) versus those receiving intravenous (IV) or subcutaneous (SC) hypomethylating agents. The analysis included 1569 patients – 10.2% receiving the oral treatment and 89.8% receiving IV therapy, and although persistence was initially comparable between the two treatment groups, after 6 months, the findings indicate an increased persistence in the DEC-C group, which Dr Zeidan hopes will translate to improved clinical outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Schrödinger, Notable, Chiesi, Mendus, Otsuka, Foran, Syros, ALX Oncology, Kura, Seattle Genetics, Servier, Boehringer-Ingelheim, Jazz, Orum, Geron, Syndax, Gilead, Zentalis, BeyondSpring, Incyte, Pfizer, Celgene/BMS, Janssen, Amgen, Agios, Daiichi Sankyo, Tyme, Taiho, AbbVie, Ionis, Takeda, Genentech, Epizyme, Lox Oncology, Novartis, Astellas, BioCryst, Regeneron
Honoraria: Schrödinger, Notable, Chiesi, Mendus, Otsuka, Foran, Syros, ALX Oncology, Kura, Seattle Genetics, Servier, Boehringer-Ingelheim, Jazz, Orum, Geron, Syndax, Gilead, Zentalis, BeyondSpring, Incyte, Pfizer, Celgene/BMS, Janssen, Amgen, Agios, Daiichi Sankyo, Tyme, Taiho, AbbVie, Ionis, Takeda, Genentech, Epizyme, Lox Oncology, Novartis, Astellas, BioCryst, Regeneron
Research Funding: Foran, Shattuck Labs, Astex
